ScripBispecific antibodies that redirect T-cells to cancer cells expressing a targeted antigen are showing impressive responses in relapsed and refractory multiple myeloma, but to date there has been littl
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Exits Gene Therapy Delivery Pact